

Red Tide: Why a Biologic, HDFx, and Magnesium Could be used to allay Inflammatory and Lung Problems Caused by Algal Blooms: Hypothesis

Burton M Altura¹⁻⁶

¹Department of Physiology & Pharmacology

²Department of Medicine

³The Center for Cardiovascular & Muscle Research

⁴The School of Graduate Studies in Molecular and Cellular Science, State university of New York Downstate Health Sciences University, Brooklyn, New York

⁵Bio-Defense Systems, Inc, Rockville Centre, New York

⁶The Magnesium Health Foundation, Patterson, CA

*Corresponding author:

Professor B. M. Altura, Box 31, Downstate Medical Center, 450 Clarkson Ave., Brooklyn, NY

Submitted: 01 Feb 2021; Accepted: 06 Feb 2021; Published: 16 Feb 2021

Citation: B. M. Altura. (2021). Red Tide: Why a Biologic, HDFx, and Magnesium Could be used to allay Inflammatory and Lung Problems Caused by Algal Blooms: Hypothesis, *J Clin Exp Immunol*, 6(1): 286-290.

Introduction

Over the past decade, there has been a growing concern over invasion of Florida Gulf Coastal Waters and beaches by several algal blooms created by “red tides”. These algal blooms create various toxins that pose high risks for marine life, livestock, birds, and humans [1, 2]. The algae become so numerous that they discolor gulf waters and beaches. Since the 1980’s, red tides have been seen in many countries throughout the globe (i.e., South America, Central America, Japan, caribbean, South Pacific regions, etc.).

The organisms primarily responsible for the red tides are microscopic algae called dinoflagellates [1]. When these blooms occur, it is not uncommon for beaches to be littered with thousands of dead fish, birds, and molluscs. These dinoflagellates produce several different neurotoxins that not only kill marine life (e.g., turtles, manatees, dolphins, etc.) and livestock, but can cause multiple inflammatory effects in humans from discomfort in the skin, rashes, burning in the eyes, throat infections, and coughing to serious lungs problems. People with serious asthmatic conditions, emphysema, or chronic lung disease could get in serious life-threatening situations. As of the moment, there are no proven countermeasures ether to treat against these neurotoxins or to prevent red tides and their effects, especially in humans.

Discovery and Development of a New Biologic Host-Defense Factor, HDFx

Our laboratories, for more than 50 years have been working on a new approach to develop host-defense factors that stimulate various arms of the innate and adaptive immune systems [3-43]. To this end, we have discovered a new host-defense factor our group

termed “HDFx” that is a conserved protein found primarily in macrophages and natural killer (NK) cells [44-48]. So far, we have found its presence in rodents, rabbits, guinea-pigs, dogs, cats, and subhuman primates.

Approximately 135 years ago, Elie Metchnikoff, the father of immunology, and Nobel laureate, hypothesized that the body, under stressful circumstances and adverse conditions, would produce powerful immunostimulants which could act on different arms of the innate immune system and serve to protect against major insults, inflammatory conditions, and diseases [49]. Metchnikoff’s early studies pointed to the important contributions of macrophages and phagocytic leukocytes to natural (innate)resistance against pathogenic bacterial and viral microorganisms. Over the past 40 years, considerable evidence has accumulated to support a strong relationship between the functional (physiological) state of the microcirculation, circulating macrophages, alveolar macrophages, NK cells, the reticuloendothelial system (RES), and “pit cells” in the liver to host-defense and resistance to pathogens, trauma, sepsis, wounding, circulatory shock and combined injuries [7, 10, 20, 21, 24, 26, 27, 30, 38, 40, 43, 50-54].

Ongoing studies from our laboratories have shown that HDFx is protective (to varying degrees) against a variety of insults ranging from hemorrhage, trauma, endotoxins, a variety of bacteria (i.e., *E. coli*, *S. enteritidis*, *C. welchii*), combined injuries, fungal toxins, sepsis, experimental NASH, and inflammatory conditions [45, 46, 48, 55]. HDFx also protects against cytokine storms as is often the cause of death in many infectious diseases [56-59]. A unique attribute of HDFx is its ability to accelerate wound healing [46].

Most importantly, HDFx has been demonstrated to inhibit release of multiple cytokines and chemokines, including TNF-alpha, IL-6, IL-8, IL-1-beta, IFN-gamma, and numerous macrophage factors [44, 56-59]. Thus, HDFx can either

prevent or ameliorate “cytokine storms” induced by gram-negative and gram-positive microorganisms, trauma, and systemic inflammatory conditions, among other dangerous bodily insults [44, 56-59].

Magnesium as a Pulmonary Vasodilator and Anti-inflammatory Agent

Approximately 50 years ago, we reported that magnesium (Mg) can be a powerful vasodilator of arteries, veins and microscopic blood vessels as well as an inhibitor of vasoconstrictor agents and pulmonary hypertension in animal models, neonates and adults [60-73]. Mg has been found, both experimentally and clinically, to be useful as an anti-inflammatory agent [74].

Suggested Use of Combined HDFx with Mg for Treatment and Amelioration of Rashes, Skin Lesions, Inflammations, and Coughing Induced by Red Tides in Humans

It is now clear, in the case of vasculitis, and red tide inflammations in humans that these insults are associated with increased levels of cytokines and chemokines (e.g., INF-alpha, IL-1-beta, IL-2, IL-4, IL-8, IL-10, TNF-alpha, MCP-1, among others) which are pro-inflammatory in nature [1, 2, 75]. We have found that rats placed on Mg deficient diets for 21 days generate all of these pro-inflammatory cytokines and chemokines, in bloods, cutaneous tissues, myocardium and blood vessel vascular and endothelial cells, and demonstrate inflammations [76, 77]. Other investigators have also reported finding many of these cytokines and chemokines in Mg deficient animals and humans [78]. Many of these cytokines and chemokines, in Mg deficient animals, were found to be associated with microvascular remodeling and pathological alterations in the postcapillary venules, the major sites of inflammatory lesions [79-81]. Under high in-vivo microscopic observation, the venules were associated with reduced lumen sizes and adherence of leukocytes and macrophages, similar to that observed in various forms of vasculitis, and most likely in cases of red tide. In view of our extensive findings, it is difficult to dismiss the probable role of a deficiency produced by red tides. Thus, we believe it is worth trying to administer Mg salts and Epsom salt baths to victims of red tides-induced inflammatory conditions.

Since our work on “HDFX” demonstrates, it poses remarkable anti-inflammatory actions and accelerates wound healing, we believe the Mg treatment should be combined with HDFx.

Conclusions and Future Thoughts

Although no “tried and true” countermeasures exist for treating the harmful effects of red tides in humans, animals and sea creatures the discovery of a new biologic, HDFx, presents cogent reasons for trying this conserved protein for its potential therapeutic actions along with Mg salts, due to their anti-inflammatory actions. HDFx has an added benefit since it accelerates wound healing. Mg has powerful vasodilator actions in the microcirculation allowing tissue perfusion and oxygenation of ischemic-inflamed tissues, as

is found in the effects of red tides on the skin and lungs. We believe a cream containing HDFx and Mg would be powerful anti-inflammatory agents in the treatment of red tide poisoning.

Acknowledgements

Most of our work on HDFx has been supported, in part, by Research Grants from The National Institute on Heart, Lung and Blood Institute. Some of our studies were initiated while we were on the faculties of The New York University School of Medicine and The Albert Einstein College of Medicine. In addition, some of our studies on HDFx and Mg were supported, in part, by several grants-in-aid from several pharmaceutical companies. The Bio-Defense Laboratories at the U.S. Naval Medical Center in Silver Springs, MD, also awarded us a grant for studies on HDFx.

References

1. Fleming LE, Kirkpatrick B, Backer LC, Walsh CJ, Nierenberg K, et al. (2011) Review of Florida red tide and human health effects. *Harmful Algae* 10: 224-233.
2. Centers for Disease Control and Prevention (2020) Morbidity and Mortality Report (MMWR) December 69: 1889-1894.
3. Altura BM, Hershey SG, Hyman C (1966) Influence of choline on the reticuloendothelial system and on survival after experimental shock. *J Reticuloendothel Soc* 3: 57-64.
4. Hershey SG, Altura BM (1966) Management of the peripheral circulation vasoactive drugs in the management of shock: A microcirculatory approach. *Schweiz Med Wschr* 96: 1467-1471; 1516-1522.
5. Hershey SG, Altura BM (1966) Effect of pretreatment with aggregate albumin on reticuloendothelial system activity and after experimental shock. *Proc Soc Exp Biol Med* 122: 1195-1199.
6. Altura BM, Thaw C, Hershey SG (1966) Role of bacterial endotoxins in intestinal ischemic (SMA) shock. *Experientia* 22: 786-788.
7. Altura BM, Hershey SG, Ali M, Thaw C (1966) Influence of tetracycline on phagocytosis, infection and resistance to experimental shock: relationship to microcirculation. *J Reticuloendothel Soc* 3: 447-467.
8. Altura BM, Hershey SG (1967) Use of reticuloendothelial phagocytic function as an index in shock therapy. *Bull NY Acad Med* 43: 259-266.
9. Altura BM, Hershey SG (1968) RES phagocytic function in trauma and adaptation to experimental shock. *Am J Physiol* 215: 1416-1419.
10. Altura BM, Hershey SG (1968) Microcirculatory basis for vasoactive therapy in shock. In: *Intermedes Proceedings 1968: Combined Injuries and Shock*, Schildt B, Thoren L, eds. Almquist and Wiksell, Stockholm 1968: 233-245.
11. Altura BM, Hershey SG (1968) Influence of vasopressor drugs on reticuloendothelial phagocytic function in experimental Shock. In: *Intermedes Proceedings 1968: Combined Injuries and Shock*, Schildt B, Thoren L, eds. Almquist and Wiksell, Stockholm 1968: 185-193.
12. Hershey SG, Altura BM (1968) Influence of RES stimulating materials compatible for man on phagocytosis and survival after experimental shock. In: *Intermedes Proceedings 1968: Combined Injuries and Shock*, Schildt B, Thoren L, eds.

- Almqvist and Wiksell, Stockholm 1968: 195-203.
13. Altura BM, Hershey SG (1968) Patterns of RES phagocytic function in trauma and experimental shock adaptation. In: *Intermedes Proceedings 1968: Combined Injuries and Shock*, Shildt B, Thoren L, eds. Almqvist and Wiksell, Stockholm, 205-213.
 14. Hershey SG, Altura BM (1969) Function of the reticuloendothelial system in experimental shock and combined injury. *Anesthesiology* 30: 138-143.
 15. Hershey SG, Altura BM (1969) The effects of vasoactive drugs on reticuloendothelial function in experimental shock and combined injury. *Anesthesiology* 30: 144-149.
 16. Altura BM, Hershey SG (1970) Effects of glyceryl trioleate on the reticuloendothelial system and survival after experimental shock. *J Pharmacol Exp Ther* 175: 555-564.
 17. Altura BM, Hershey SG (1971) Acute intestinal ischemic shock and reticuloendothelial system function. *J of Reticuloendothelial Soc* 10: 361-371.
 18. Altura BM, Hershey SG (1972) Sequential changes in reticuloendothelial system function after acute hemorrhage. *Proc Soc Exp Biol Med* 139: 935-939.
 19. Altura BM, Hershey SG (1973) Reticuloendothelial function in experimental injury and tolerance to shock. *Adv Exp Med Biol* 33: 549-569.
 20. Altura BM, Hershey SG (1974) Endotoxemia in the rat: Role of blood coagulation and leukocytes in progression of the syndrome. *Circulatory Shock* 1: 113-122.
 21. Altura BM, Altura BT (1974) Peripheral vascular actions of glucocorticoids and their relationship to protection in circulatory shock. *J Pharmacol Exp Ther* 190: 300-315.
 22. Halevy S, Altura BM (1974) Genetic factors influencing resistance to trauma. *Circulatory Shock* 1: 287-293.
 23. Altura BM (1974) Hemorrhagic shock and reticuloendothelial system phagocytic function in pathogen-free animals. *Circulatory Shock* 1: 295-300.
 24. Altura BM, Altura BT, Hershey SG (1974) Pharmacodynamic actions of corticosteroids on the microcirculation and vascular smooth muscle. In: *Steroids and Shock*, Glenn TM, ed. University Park Press, Baltimore 1974: 67-88.
 25. Altura BM (1975) Sex and estrogens and responsiveness of terminal arterioles to neurohypophyseal hormones and catecholamines. *J Pharmacol Exp Ther* 193: 403-412.
 26. Altura Bm (1976) DPAVP: A vasopressin analog with selective microvascular and RES actions for the treatment of circulatory shock in rats. *Eur J Pharmacol* 37: 155-168.
 27. Altura BM (1976) A microcirculatory approach to the treatment of circulatory shock using a new analog of vasopressin, [2-phenylalanine, 8-ornithine]-vasopressin. *J Pharmacol Exp Ther* 198: 187-196.
 28. Altura Bm (1976) Sex and estrogens in protection against circulatory stress reactions. *Am J Physiol* 231: 842-847.
 29. Halevy S, Altura BM (1976) Indomethacin protection in traumatic shock. *Circulatory Shock* 3: 299-302.
 30. Altura BM (1976) Importance of sex and estrogens in amelioration of lethal circulatory stress reactions: Relationship to microcirculation and reticuloendothelial system function. In: *Adv Exp Med Biol* 64: *Atherosclerosis in Drug Discovery*, Day Fe, ed. Plenum Press, New York 1976: 289-312.
 31. Altura BM, Halevy S (1978) Beneficial and detrimental actions of H1- and H2-histamine receptor antagonists in circulatory shock. *PNAS USA* 75: 2941-2944.
 32. Altura BM (1979) Reticuloendothelial system (RES) phagocytic depression in shock is ameliorated by H1-receptor anti-histamine. *Eur J Pharmacol* 59: 165-167.
 33. Altura BM, Gebrewold A (1980) Prophylactic administration of antibiotics compromises reticuloendothelial system function and exacerbates shock mortality in rats. *Br J Pharmacol* 68: 19-21.
 34. Altura BM (1980) Reticuloendothelial and neuroendocrine stimulation in shock therapy. *Adv Shock Res* 3: 2-25.
 35. Halevy S, Spector S, Altura BM (1980) Serum serotonin levels determined by radioimmunoassay in normal male and female rats and after intestinal ischemia shock. *Biochem Med* 23: 236-238.
 36. Altura BM (1980) Recent progress in pathophysiology of shock: Reticuloendothelial and neuro-endocrine stimulation. *J Clin Anesth* 4: 745-758.
 37. Altura BM (1980) Reticuloendothelial function and humoral factors in shock and trauma. *Reanimation* 11: 73-91.
 38. Altura BM (1980) Reticuloendothelial cells and host defense. *Adv Microcirculation* 9: 73-91.
 39. Altura BM (1981) Pharmacology of venules: Some current concepts and clinical potential. *J Cardiovasc Pharmacol* 3: 1413-1428.
 40. Altura BM (1982) Reticuloendothelial system function and histamine release in shock and trauma. Relationship to microcirculation. *Klin Wochschr* 60: 882-890.
 41. Altura BM, Altura BT (1982) Factors affecting responsiveness of blood vessels to prostaglandins and other chemical mediators of injury and shock. In: *Role of Chemical Mediators in the Pathophysiology of Acute Illness and Injury*, McConn R, ed. Raven Press, New York 1982: 45-63.
 42. Altura BM (1985) Role of reticuloendothelial and endothelial cells in response to shock and trauma. In: *Pathophysiology of Combined Injury and Trauma*, Conklin JT, ed. University Park Press, Baltimore.
 43. Altura BM (1986) Endothelial and reticuloendothelial cell function: roles in injury and low-flow states. In: *The Scientific Basis for the Care of the Critical Ill*, Little RA, Frayn KN, eds. Manchester University Press, Manchester, UK 1986: 259-274.
 44. Altura BM, Gebrewold A, Carella A (2009) A novel biologic immunomodulator, HDFx, protects against hemorrhage, endotoxins, and traumatic injury: potential relevance to emerging diseases. *Int J Clin and Exp Med* 2: 266-279.
 45. Altura BM, Gebrewold A, Carella A (2011) HDFx: A novel biologic immunomodulator is therapeutically effective in hemorrhage and intestinal ischemic shock < importance of microcirculatory-immunological interactions and their potential implications for the warfighter and disaster victims. *Int J Clin and Exp Med* 4: 331-340.
 46. Altura BM, Gebrewold A, Carella A, Altura BT (2012) HDFx: A recently discovered immunomodulator accelerates wound healing and is suggestive of unique regenerative powers: Potential implications for the warfighter and disaster victims. *Int J Clin and Exp Med* 5: 289-295.
 47. Altura BM, Carella A, Gebrewold A (2016) A recently discov-

- ered biologic and its potential use in prevention and treatment of hemorrhagic fever viruses and antibiotic resistant superbugs. *J Hematol and Thromboembolic Dis* 4: 252.
48. Altura BM, Gebrewold A, Carella A, Altura BT (2016) HDFx; a novel immunomodulator and potential superbug super warrior for hospitalized patients and battlefield casualties. *Int J Vaccines and Res* 3: 1-3.
 49. Metchnikoff E (1884) Untersuchung ueber die intracellulare Verdauung bei wirbellosen Thieren. *Arbeiten aus dem Zoologischen Institut zu Wien* 5: 141-168.
 50. Ulevitch RJ, Mathison JC, Tobias RS (1983) The role of the macrophage in host defense to bacterial endotoxins. In: *The Pathophysiology of Combined Injury and Shock* 5: 87-92.
 51. Majno G, Joris I (2004) *Cells, Tissues and Diseases*, 2nd ed. Oxford University Press, New York.
 52. Angele MK, Chaudry IH (2005) Surgical trauma and immunosuppression: Pathophysiology and potential immunomodulatory approaches. *Langenbecks Arch Surg* 390: 334-341.
 53. Caligiuri MA (2008) Human natural killer cells. *Blood* 112: 461-469.
 54. Murphy K, Weaver C (2016) *Janeway's Immunology*, 9th ed. Garland Science, New York.
 55. Altura BM, Gebrewold A, Carella A, Altura BT (2016) HDFx: A potential new treatment and prophylactic against nonalcoholic steatohepatitis (NASH) and subsequent hepatocellular carcinomas: is hypomagnesemia a complication of the disease? *J Alcoholism & Drug Dep* 4: 1000-e133.
 56. Altura BM, Gebrewold A, Carella A, Altura BT (2017) HDFx: A novel immunomodulator and potential fighter against cytokine storms in inflammatory and septic conditions in dogs and farm animals. *Int J Veterinary Health Sciences & Res* 2e: 1-3.
 57. Altura BM, Altura BT (2017) HDFx: A novel immunomodulator and potential fighter against cytokine storms in viral flu infections. *SciFed J of Flu Science* 1: 1-4.
 58. Altura BM, Gootman PM, Gebrewold A, Mestel LS, Carella A (2020) HDFx: A stress-induced biologic that inhibits endotoxin-induced fevers and depression in cardiac hemodynamics in rabbits, guinea-pigs and rats: Potential relevance to coronavirus fevers and role of NF-kB. *J Clin and Exp Cardiol* 11: e654.
 59. Altura BM, Gebrewold A, Carella A (2020) Why a stress protein, HDFx, may be useful as an ameliorative in the treatment of cytokine storms, depression in cardiac hemodynamics and coagulopathies in coronavirus diseases such as COVID-19, SARS and MERS. *EC Emergency and Crit Care* 4: 92-97.
 60. Altura BM, Altura BT (1974) Magnesium and contraction of arterial smooth muscle. *Microvasc Res* 7: 145-155.
 61. Altura BM, Altura BT (1977) Extracellular magnesium and contraction of vascular smooth muscle. In: *Excitation-Contraction Coupling of Smooth Muscle*, Casteels R, Godfraind T, Ruegg JC, eds. Borth Holland Publ Co, Amsterdam 1977: 137-144.
 62. Altura BM, Altura BT (1978) Magnesium and vascular tone and reactivity. *Blood Vessels* 15: 5-16.
 63. Turlapaty PDMV, Altura BM (1980) Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. *Science* 208: 198-200.
 64. Altura BT, Altura BM (1980) Withdrawal of magnesium causes vasospasm while elevated magnesium produces relaxation of tone in cerebral arteries. *Neurosci Lett* 20: 323-327.
 65. Altura BM, Altura Bt, Gebrewold A, Ising H, Gunther T (1984) Magnesium deficiency and hypertension: Correlation between magnesium-deficient diets and microcirculatory changes in situ. *Science* 223: 1315-1317.
 66. Nagai I, Gebrewold A, Altura BT, Altura BM (1988) Magnesium salts exert direct vasodilator effects on rat cremaster muscle microcirculation. *Arch Int Pharmacodynamie* 294: 194-214.
 67. Nishio A, Gebrewold A, Altura BT, Altura BM (1988) Comparative effects of magnesium salts on reactivity of arterioles and venules to constrictor agents: An in situ study on microcirculation. *J Pharmacol Exp Ther* 246: 855-865.
 68. Nishio A, Gebrewold A, Altura BT, Altura BM (1989) Comparative vasodilator effects of magnesium salts on rat mesenteric arterioles and venules. *Arch Int Pharmacodynamie* 298: 139-163.
 69. Mathew R, Gloster Bs, Altura BT, Altura BM (1988) Magnesium aspartate hydrochloride attenuates monocrotaline-induced pulmonary artery hypertension. *Clin Sci* 75: 661-667.
 70. Evans R, Altura BT, Genthner S, Rich J, Bauman J, Altura BM (1996) Altered ionized magnesium and calcium in patients with primary pulmonary hypertension. *Chest* 110: 108S.
 71. Wang D, Zhu Z-L, Lin D-C, Yao R-H, Zhu W-J, et al. (2020) Magnesium supplementation attenuates pulmonary hypertension via regulation of magnesium transporters. *Hypertension* 7: 617-631.
 72. Altura BM, Gebrewold A, Carella A, Shah NC, Shah GJ, et al. (2020) HDFx and magnesium in combination ameliorates experimental pulmonary hypertension: Relevance to treatment of pulmonary hypertension in humans and newborns and the roles of hypomagnesemia, ceramides and PAF. *EC Cardiology* 7: 1-10.
 73. Saleh AA, Alyassen AA, Alhadid AM, Ayash FF (2020) Persistent pulmonary hypertension in the newborn. *JRMS* 27: 10.
 74. Dean C (2017) *The Miracle of Magnesium*. Ballantine Books, New York.
 75. Altura BM, Gebrewold A, Carella A, Shah NC, Shah GJ, et al. (2016) Why vasculitis probably can be ameliorated with magnesium and antagonists of ceramides and platelet-activating factor. *Surgery & Case Studies: Open Access J* 3: 1-4.
 76. Altura BM, Shah NC, Shah GJ, Zhang A, Li W, et al. (2012) Short-term magnesium deficiency upregulates ceramide synthase in cardiovascular tissues and cells: crosstalk among cytokines, Mg, NF-kB and de novo ceramide. *Am J Physiol Heart Circ Physiol* 302: H319-H332.
 77. Altura BM, Shah NC, Shah GJ, Zhang A, Li W, et al. (2014) Short-term magnesium deficiency upregulates protein kinase C isoforms in cardiovascular tissues and cells: relation to NF-kB, cytokines, ceramide salvage sphingolipid pathway and PKC-zeta: hypothesis and review. *Int J Clin Exp Med* 6: 1-21.
 78. Weglicki WB (2012) Hypomagnesemia and inflammation. *Annu Rev Nutr* 32: 55-72.
 79. Altura BM, Altura BT (2007) Magnesium: forgotten mineral in cardiovascular biology and angiogenesis. In: *New Perspectives in Magnesium Research*, Nishizawa N, Morii H, Durlach J, eds. Kluwer, Amsterdam 2007: 239-260.
 80. Altura BM, Zhang A, Zheng T, Shah NC, Shah GJ, et al. (2016)

The expression of platelet-activating factor is induced by low extracellular Mg in aortic, cerebral and neonatal coronary vascular smooth muscle; crosstalk with ceramide production, NF-kB and proto-oncogenes: Possible links to atherogenesis and sudden cardiac death in children and infants, and aging: hypothesis, review and viewpoint. *Int J Cardiol Res* 3: 47-67.

81. Altura BM, Shah NC, Shah GJ, Altura BT (2018) Magnesium deficiency, sphingolipids and telomerase: relevance to atherogenesis, cardiovascular disease and aging. In: *Handbook of Famine, Starvation and Nutrient Deprivation*, Preedy VL, ed. Springer, Berlin.

Copyright: ©2021 B. M. Altura, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.